logo-loader
viewAmryt Pharma PLC

Full interview: Amryt Pharma well positioned to become 'global leader in rare and orphan diseases'

Amryt Pharma PLC's (LON:AMYT) Rory Nealon talks Proactive London's Andrew Scott through their trading update for the nine months to the end of September 2019.

It's a period in which Amryt completed the acquisition of Aegerion Pharmaceuticals Inc and saw the firm go from a single-product, Europe-focused business to an operation with infrastructure around the world and two orphan treatments.

Quick facts: Amryt Pharma PLC

Price: 128.5 GBX

AIM:AMYT
Market: AIM
Market Cap: £198.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Arc Minerals reports further high grade copper...

Headlines from the Proactive UK newsroom. Arc Minerals (LON:ARCM) has reported yet more good copper grades from shallow drilling at Cheyeza East in Zambia. Results this time includes metal indications to the southeast and northwest, which suggest the resource is expanding – according to the...

on 5/11/19

2 min read